Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (August 2017)

Tuesday, September 19, 2017

In August 2017, Russia imported 45.6 bln RUB worth of ready-made drugs (free circulation prices, VAT included), which is 13% higher than that of the same period of 2016, and 15.1 bln RUB worth of in-bulk drugs, which is 42% higher than that of the same period of 2016 (best dynamics over the past 16 months.) Between January and August 2017, Russia imported 390.4 bln RUB worth of pharmaceutical drugs, which is 4.2% higher than that of the same period of 2016.

The import of ready-made drugs accounts for 327 bln RUB, with an 8.9% increase. Despite the promising August performance, the in-bulk import has fallen by 14.8% (more than 11 bln RUN) in monetary terms.

In physical terms, Russia imported 1.3 bln units between January and August, which is 6.2% higher than that of the same period of 2016. If calculated in minimum dosage units (MDU), Russia imported 23.2 MDUs of ready-made drugs, which is 4.2% lower than that of the same period of 2016. The in-bulk import accounts for 2.8 bln MDUs, which is a 3.7% increase, despite a 6% decrease in physical terms. Revlimid by Celgene contributed the most for the rise in the in-bulk import in monetary terms in August 2016, with Pharmstandard importing 5.2 bln RUB worth of the drug. In 2016, Pharmstandard imported 7.3 and 2 bln RUB worth of Revlimid in April and September, respectively.

Read more about pharmaceutical drug import to Russia (July performance) here:

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2016 – August 2017)